ArticleOrphanet journal of rare diseases2024

Heparan sulfate in cerebrospinal fluid as a biomarker to assess disease severity and for treatment monitoring in patients with Mucopolysaccharidosis Type II: a position statement.

Roberto Giugliani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.